Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults: a population-based study.

Ochoa-Gondar O, Hospital I, Vila-Corcoles A, Aragon M, Jariod M, de Diego C, Satue E; EPIVAC Study Group.

BMC Public Health. 2017 Jun 29;17(1):610. doi: 10.1186/s12889-017-4529-8.

2.

Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.

Vila-Corcoles A, Ochoa-Gondar O, Hospital I, de Diego C, Satué E, Bladé J, Ansa X, Guzmán JA, Salsench E, Ramos F.

Hum Vaccin Immunother. 2016 Nov;12(11):2953-2958. Epub 2016 Jul 25.

3.

Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study.

Almirall J, Serra-Prat M, Bolíbar I, Palomera E, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A; Study Group of Community-Acquired Pneumonia in Catalan Countries (PACAP).

BMJ Open. 2014 Jun 13;4(6):e005133. doi: 10.1136/bmjopen-2014-005133.

4.

Validation of the CORB75 (confusion, oxygen saturation, respiratory rate, blood pressure, and age ≥ 75 years) as a simpler pneumonia severity rule.

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Hospital I, Salsench E, Ansa X, Saun N; EPIVAC Study Group.

Infection. 2014 Apr;42(2):371-8. doi: 10.1007/s15010-013-0565-1. Epub 2013 Nov 29.

PMID:
24293055
5.

Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia.

Almirall J, Bolíbar I, Serra-Prat M, Palomera E, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A; Community-Acquired Pneumonia in Catalan Countries (PACAP).

PLoS One. 2013 Sep 5;8(9):e73271. doi: 10.1371/journal.pone.0073271. eCollection 2013.

6.

Inhaled drugs as risk factors for community-acquired pneumonia.

Almirall J, Bolíbar I, Serra-Prat M, Palomera E, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A; Community-Acquired Pneumonia in Catalan Countries.

Eur Respir J. 2010 Nov;36(5):1080-7. doi: 10.1183/09031936.00022909. Epub 2010 Jun 4.

7.

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X.

Vaccine. 2009 Mar 4;27(10):1504-10. doi: 10.1016/j.vaccine.2009.01.013. Epub 2009 Jan 24.

PMID:
19171174
8.

Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease.

de Diego C, Vila-Córcoles A, Ochoa O, Rodriguez-Blanco T, Salsench E, Hospital I, Bejarano F, Del Puy Muniain M, Fortin M, Canals M; EPIVAC Study Group.

Eur Heart J. 2009 Jan;30(2):209-16. doi: 10.1093/eurheartj/ehn498. Epub 2008 Nov 8.

PMID:
18997178
9.

The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study.

Ochoa-Gondar O, Vila-Córcoles A, de Diego C, Arija V, Maxenchs M, Grive M, Martin E, Pinyol JL; EVAN-65 Study Group.

BMC Public Health. 2008 Jun 27;8:222. doi: 10.1186/1471-2458-8-222.

10.

Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.

Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, Raga X, Gomez F, Valdivieso E, Fuentes C, Palacios L; EVAN Study Group.

Vaccine. 2008 Apr 7;26(16):1955-62. doi: 10.1016/j.vaccine.2008.02.021. Epub 2008 Feb 27.

PMID:
18343541
11.

New evidence of risk factors for community-acquired pneumonia: a population-based study.

Almirall J, Bolíbar I, Serra-Prat M, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A; Community-Acquired Pneumonia in Catalan Countries (PACAP) Study Group.

Eur Respir J. 2008 Jun;31(6):1274-84. doi: 10.1183/09031936.00095807. Epub 2008 Jan 23.

12.

Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group.

Clin Infect Dis. 2006 Oct 1;43(7):860-8. Epub 2006 Aug 21.

PMID:
16941367
13.

Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.

Vila-Córcoles A, Ochoa-Gondar O, Llor C, Hospital I, Rodríguez T, Gómez A.

Eur Respir J. 2005 Dec;26(6):1086-91.

Supplemental Content

Loading ...
Support Center